Clinical Trials Logo

Filter by:
NCT ID: NCT02247232 Completed - Cervical Cancer Clinical Trials

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer

Start date: December 2014
Phase: Phase 3
Study type: Interventional

This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.

NCT ID: NCT02246777 Completed - Glaucoma Clinical Trials

Alcon® Ex-PRESS® Glaucoma Filtration Device in Japanese Patients

Start date: February 26, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of the Alcon Ex-PRESS® Glaucoma Filtration Device (Ex-PRESS) in Japanese subjects with normal tension glaucoma.

NCT ID: NCT02246478 Completed - Clinical trials for Duchenne Muscular Dystrophy

A Study of TAS-205 for Duchenne Muscular Dystrophy

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy.

NCT ID: NCT02246049 Completed - Clinical trials for Colorectal Neoplasms

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

QUATTRO
Start date: May 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.

NCT ID: NCT02242045 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Start date: October 1, 2014
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL).

NCT ID: NCT02240680 Completed - Clinical trials for Diabetes Mellitus, Type 2

Linagliptin as Add on to Basal Insulin in the Elderly

Start date: September 23, 2014
Phase: Phase 4
Study type: Interventional

To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older, with Type 2 Diabetes Mellitus and insufficient glycaemic control.Stable background therapy of metformin and/or alpha-glucosidase inhibitors is also allowed. In addition, this trial will assess if linagliptin reduces the risk of hypoglycaemia when added to background basal insulin therapy. The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in glycosylated Haemoglobin, a well-accepted measurement of chronic glycaemic control.

NCT ID: NCT02240433 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)

Start date: November 12, 2014
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.

NCT ID: NCT02239380 Completed - Status Epilepticus Clinical Trials

Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

Start date: November 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy, safety and pharmacokinetics of Lorazepam on Japanese patients with Status Epilepticus or Repetitive Status Eplilepticus.

NCT ID: NCT02239120 Completed - Stroke Clinical Trials

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Start date: November 27, 2014
Phase: Phase 3
Study type: Interventional

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).

NCT ID: NCT02238847 Completed - Pancreatic Cancer Clinical Trials

Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy

Start date: March 24, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre-operative management of biliary obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy.